Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a leading stockholder rights law firm, has…
Yale founders raise $3.1M in 14 days to build Series, the anti-Facebook
Connecticut, April 04, 2025 (GLOBE NEWSWIRE) -- Social networking has become synonymous…
FLNC NEWS: Johnson Fistel Continues Investigation of Fluence Energy, Shareholders are Encouraged to Contact the Law Firm to Learn More About Their Rights
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, LLP is investigating whether Fluence Energy, Inc. (NASDAQ:…
Academia and Industry Combine Insights in Cornell Convenes Discussion on Tokenization of Real-World Assets
ITHACA, N.Y., Feb. 28, 2025 /PRNewswire/ -- Fintech at Cornell, an Initiative…
Carvana, Jimmie Johnson, and Shaquille ONeal Settle the Score With One-of-a-Kind Paint Scheme for Daytona
Carvana Brings Shaq’s Vision to Life on Jimmie Johnson’s No. 84 ToyotaPHOENIX--(BUSINESS…
Executive Counseling Offers Free Initial Consultation for Mental Health Services
Executive Counseling, led by Dr. Austin Johnson, now offers free initial consultations…
MGP Ingredients, Inc. Class Action Lawsuit Alert: Johnson Fistel Announces Shareholders with Losses Should Contact the Law Firm for More Information
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, LLP announces that a class action lawsuit has…
Advantage Solutions hires George Johnson as chief workforce operations officer
Johnson brings a wealth of labor expertise to strengthen client service, enhance…
European Commission approves RYBREVANT (amivantamab) in combination with LAZCLUZE (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
This multitargeted, chemotherapy-free combination demonstrated superiority over osimertinib monotherapy for the first-line…
DARZALEX (daratumumab) subcutaneous formulation shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smouldering multiple myeloma
First subcutaneous anti-CD38 therapy to demonstrate potential to prevent end-organ damage, and…